Heterobicyclic Carboxamides as Inhibitors for Kinases
申请人:Bold Guido
公开号:US20090030009A1
公开(公告)日:2009-01-29
The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.
Heterobicyclic carboxamides as inhibitors for kinases
申请人:Novartis AG
公开号:US08058276B2
公开(公告)日:2011-11-15
The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.
HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES
申请人:NOVARTIS AG
公开号:EP1996578A1
公开(公告)日:2008-12-03
US8058276B2
申请人:——
公开号:US8058276B2
公开(公告)日:2011-11-15
[EN] HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES<br/>[FR] CARBOXAMIDES HÉTÉROBICYCLIQUES COMME INHIBITEURS DE KINASES
申请人:NOVARTIS AG
公开号:WO2008009487A1
公开(公告)日:2008-01-24
[EN] The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases. [FR] L'invention concerne de nouveaux composés organiques de formule (I) et leur utilisation dans le traitement du corps humain ou animal, des compositions pharmaceutiques contenant un composé de formule (I) et l'utilisation d'un composé de formule (I) dans la préparation de compositions pharmaceutiques à utiliser dans le traitement de maladies dépendant des protéines kinases, notamment de maladies prolifératives, telles que des maladies tumorales en particulier.